SCHEMBL1655813

SCHEMBL1655813

CCNC(=O)CI

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL181355 0.97
SCHEMBL25682240 0.90 MCL1 (0.41)
SCHEMBL4075839 0.79 NPC1 (0.37)
SCHEMBL499584 0.79
Pyrene SCHEMBL28026667 0.78 KDM4E (0.47)
SCHEMBL13194213 0.78
SCHEMBL10050997 0.78
SCHEMBL5909428 0.78 MCL1 (0.55)
SCHEMBL18519236 0.76 MEN1 (0.61)
SCHEMBL134099 0.75 ALDH1A1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250306032-A1 METHODS FOR IDENTIFYING REACTIVE FUNCTIONAL CYSTEINES IN NUCLEAR PROTEINS TALUS BIOSCIENCE, INC. 2025-10-02 US disclosed
EP-4526686-A1 METHODS FOR IDENTIFYING REACTIVE FUNCTIONAL CYSTEINES IN NUCLEAR PROTEINS Talus Bioscience, Inc. (US) 2025-03-26 EP disclosed
CN-110179974-B Vaccine 葛兰素史密丝克莱恩生物有限公司 2024-01-09 CN disclosed
US-20230405104-A1 PROTEOGLYCAN CONJUGATE AND APPLICATION THEREOF SHANGHAI REINOVAX BIOLOGICS CO., LTD (CN) 2023-12-21 US disclosed
WO-2023225568-A1 METHODS FOR IDENTIFYING REACTIVE FUNCTIONAL CYSTEINES IN NUCLEAR PROTEINS TALUS BIOSCIENCE, INC. (US) 2023-11-23 WO disclosed
US-20230270876-A1 SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES NOVARTIS AG (CH) 2023-08-31 US disclosed
EP-4234572-A1 PROTEOGLYCAN CONJUGATE AND APPLICATION THEREOF Shanghai Reinovax Biologics Co., Ltd (CN) 2023-08-30 EP disclosed
CN-116507359-A Protein polysaccharide conjugate and application thereof 上海瑞宙生物科技有限公司 2023-07-28 CN disclosed
US-20220143166-A1 MULTIVALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE VACCINE BIOLOGICAL E LIMITED (IN) 2022-05-12 US disclosed
WO-2021214179-A2 SYNTHETIC STREPTOCOCCUS PNEUMONIAE SACCHARIDE CONJUGATES TO CONSERVED MEMBRANE PROTEIN MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2021-10-28 WO disclosed
EP-1968631-A2 VACCINE GlaxoSmithKline Biologicals S.A. (BE) 2008-09-17 EP disclosed
EP-1962899-A2 PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE GlaxoSmithKline Biologicals S.A. (BE) 2008-09-03 EP disclosed
WO-2007116028-A2 CONJUGATE VACCINES GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) 2007-10-18 WO disclosed
WO-2007071710-A2 VACCINE COMPRISING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CONJUGATES GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2007-06-28 WO disclosed
WO-2007071711-A2 VACCINE GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2007-06-28 WO disclosed
WO-2007071707-A2 PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2007-06-28 WO disclosed
US-7052916-B2 Polypeptide analyses using stable isotope labeling IMMUNEX CORPORATION (US) 2006-05-30 US disclosed
US-20030219838-A1 Polypeptide analyses using stable isotope labeling IMMUNEX CORPORATION 2003-11-27 US disclosed
US-20030108959-A1 Treating diseases mediated by metalloprotease-shed proteins IMMUNEX CORPORATION 2003-06-12 US disclosed
WO-2003036264-A2 TREATING DISEASES MEDIATED BY METALLOPROTEASE-SHED PROTEINS IMMUNEX CORPORATION (US) 2003-05-01 WO disclosed